Neddylation inhibitor MLN4924 induces G₂ cell cycle arrest, DNA damage and sensitizes esophageal squamous cell carcinoma cells to cisplatin

SHAN LIN¹*, ZHAOYANG SHANG¹*, SHUO LI¹, PENG GAO¹, YI ZHANG¹, SHUAIHENG HOU¹, PENG QIN², ZIMING DONG¹, TAO HU¹ and PING CHEN¹

¹Department of Basic Science of Oncology, College of Basic Medical Sciences, Zhengzhou University, Collaborative Innovation Center of Henan Province for Cancer Chemoprevention, Zhengzhou, Henan 450001; ²Department of Immunotherapy, Henan Cancer Hospital and Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450008, P.R. China

Received October 23, 2016; Accepted November 2, 2017

DOI: 10.3892/ol.2017.7616

Abstract. Inhibiting the protein neddylation pathway using the NEDD8-activating enzyme inhibitor MLN4924 represents an attractive anticancer strategy having been demonstrated to exhibit promising anticancer efficacy and with tolerable levels of toxicity; however, the mechanism by which MLN4924 inhibits cell proliferation in human esophageal squamous cell carcinoma (ESCC) cells requires further investigation. The present study revealed that MLN4924 treatment led to G₂ cell cycle arrest and enhanced the protein stability of Wee1-like protein kinase and cyclin dependent protein kinase inhibitor 1A and B and p27. Furthermore, MLN4924 induced DNA damage and sensitized esophageal cancer cells to cisplatin by enhancing apoptosis. These findings extend the understanding of the function and mechanism of MLN4924 in ESCC and provide further evidence for the future development of neddylation inhibitors in clinical trials of esophageal cancer therapy, either alone or in combination.

Introduction

Esophageal squamous cell carcinoma (ESCC) is a prominent subtype of esophageal cancer and has the fourth-highest incidence of cancer-associated mortality in China, 2015 (1).

Besides surgery, the current treatment options for esophageal cancer include chemoradiotherapy and chemotherapy, which is often accompanied by high toxicity and acquired therapeutic resistance (2). It is therefore urgent to identify novel drugs and regimens for the treatment of esophageal cancer.

Protein neddylation is a novel regulatory post-translational modification pathway of, in which ubiquitin-like molecule neural precursor cell expressed, developmentally downregulated 8 (NEDD8) was added to substrate proteins via a sequential enzymatic process, which includes the NEDD8-activating enzyme E1 (NAE), NEDD8-conjugating enzyme E2 and substrate-specific NEDD8-E3 ligases (3-5). The best-characterized substrates of neddylation are cullin family proteins (6), which are important skeleton protein of Cullin-RING E3 ligases (CRLs) (6). Previous studies demonstrated that the hyperactivated neddylation pathway and abnormally activated CRL E3 ligases serve important functions in disease progression, including poorer patient overall survival rates (7-11). These results indicate that the neddylation pathway is a potential anticancer target.

MLN4924 has been shown to function as a potent and selective inhibitor of NEDD8-activating enzyme (NAE) (3); previous studies revealed that MLN4924 inhibits cancer cell growth in vitro and in vivo by inactivating CRLs and causing the accumulation of substrates (12-16). Previously, MLN4924 exhibited attractive pharmacodynamic effects in phase I studies in patients with advanced solid tumors, relapsed/refractory lymphoma and metastatic melanoma for its tolerable safety profile (17-19). MLN4924 may function as a novel chemosensitizer or radiosensitizer in multiple types of cancer (20-24). These results indicate that targeting the neddylation pathway may represent an attractive anticancer strategy, either alone or in combination with other therapies.

To further explore the effect and mechanism of MLN4924 on esophageal cancer cell growth alone or in combination with cisplatin (CDDP), a standard chemotherapy drug for patients with esophageal cancer, the cell cycle arrest induced by MLN4924 treatment and the stability of cell-cycle associated proteins, including cyclin-dependent kinase inhibitor 1
(CDKN1A; also known as p21), CDKN1B (also known as p27) and Wee1-like protein kinase (Weel) were investigated. In addition, MLN4924 and CDDP have been demonstrated to induce DNA damage, therefore the combinational effect on DNA damage and apoptosis was also examined.

**Materials and methods**

**Cell lines, culture and reagents.** Human ESCC EC1 and Kyse450 cell lines were kindly gifted from Professor Zhao (Zhengzhou University, Zhengzhou, China) and cultured in Dulbecco’s modified Eagle’s medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) containing 10% fetal bovine serum (FBS; Biochrom, Ltd., Cambridge, UK) at 37°C with 5% CO₂. MLN4924 was synthesized and prepared as previously described (7,25).

**Cell viability.** Cell viability was detected using an ATPLite Luminescence Assay kit (PerkinElmer, Inc., Waltham, MA, USA) as previously described (7,25). Briefly, cells were seeded in 96-well plates (3x10³ cells/well) and treated with dimethyl sulfoxide (DMSO; 0.1%) or MLN4924 (0.0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0 μM). Cell proliferation was determined at 24, 48 and 72 h with indicated concentration (0.0, 0.1, 0.2, 0.3, 0.4, 0.6, 0.8, 1.0 μM) using the assay kit according to the manufacturer’s instructions.

**Clonogenic assay.** A total of 500 cells were seeded into 6-well plates in triplicate, treated with DMSO (0.1%), MLN4924 (0.05 μM), CDDP (MedChem Express Co., Ltd., Shanghai, China) (1 μg/ml) or MLN4924 (0.05 μM) + CDDP (1 μg/ml) and then incubated for 12 days. The colonies were fixed with 4% paraformaldehyde for 30 min at room temperature and stained with crystal violet for 30 min at room temperature, then incubated for 12 days. The colonies were fixed with 4% paraformaldehyde for 30 min at room temperature and stained with crystal violet for 30 min at room temperature. The colonies were counted under light field of inverted microscope at x100 magnification, and captured using Gel Doc™ XR+ Gel Documentation System (Bio-Rad Laboratories, Inc., Shanghai, China). Colonies comprising 50 cells or more were counted.

**Cell cycle analysis.** Cells treated with MLN4924 at indicated concentrations were harvested, fixed in 70% ethanol at -20°C and then stained with 50 μg/ml propidium iodide (PI) containing 30 μg/ml RNase A (both from Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) at 37°C for 30 min and analyzed for cell-cycle profile by flow cytometry (Becton Dickinson FACScan; Becton-Dickinson, San Jose, CA, USA). Data were analyzed with ModFit LT 3.1 software (Verity Software House, Inc., Topsham, ME, USA).

**Western blotting.** EC1 and Kyse450 were treated with MLN4924 (0.1, 0.3, 0.6 μM) or DMSO (0.1%) for 72 h. Then the protein was extracted using radioimmunoprecipitation buffer (Beyotime Institute of Biotechnology, Jiangsu, China) and protein concentration was determined using BCA kit (Beyotime Institute of Biotechnology). When detected, 50 μg proteins were loaded per lane with 2% SDS. The proteins were transferred to polyvinylidene fluoride membrane and blocked with 5% skim milk for 2 h at room temperature. The protein was detected using antibodies against p21 (cat. no. 2947), p27 (cat. no. 3686), Weel (cat. no. 4936), cyclin B (cat. no. 12231), Phospho-Histone H3 (Ser10; cat. no. 3377), origin recognition complex (ORC1; cat. no. 4731), DNA replication factor Cdt1 (CDT1; cat. no. 8064), serine/threonine-protein kinase Chk1 (CHK1; cat. no. 2360), CHK2 (cat. no. 2662), p-histone H2AX at Ser139 (γH2AX; cat. no. 9718), cleaved caspase-3 (cat. no. 9664), cleaved poly(ADP-ribose) polymerase (PARP; cat. no. 5625), GAPDH (cat. no. 2118) (all from Cell Signaling Technology, Inc., Danvers, MA, USA) and p-CHK1 (cat. no. ab58567), p-CHK2 (cat. no. ab59408) (both from Abcam, Cambridge, UK). All the primary antibodies were diluted in 1:1,000 and incubated at 4°C overnight. Secondary antibodies peroxidase-conjugated goat anti-mouse IgG (cat. no. ZB-2305) and peroxidase-conjugated goat anti-rabbit IgG (cat. no. ZB-2301) were purchased from ZGSB-Bio, Inc., (Beijing, China). The membrane was incubated with secondary antibodies (1:3,000) for 2 h at room temperature. Then the membrane was detected using an ECL Kit (Beyotime Institute of Biotechnology).

**Apoptosis detection.** Cells were treated with the indicated concentration of MLN4924 (0.3 μM), CDDP (1.6 μg/ml) and MLN4924 (0.3 μM) + CDDP (1.6 μg/ml) for 72 h. Apoptosis was determined with the Annexin V-Fluorescein Isothiocyanate/PI Apoptosis kit and CaspGLOW Fluorescein Active Caspase-3 Staining kit (both from BioVision, Inc., Milpitas, CA, USA), according to the manufacturer’s instructions. Using Annexin V-Fluorescein Isothiocyanate/PI, apoptosis and the activity of caspase-3 were detected using a flow cytometer, and results were analyzed using Summit 6.1 software (BD Biosciences, Franklin Lakes, NJ, USA).

**Immunofluorescence staining.** EC1 and Kyse450 were treated with MLN4924 using 0.0, 0.3, 0.6 or 1.0 μM and fixed with 4% paraformaldehyde for 30 min at room temperature, permeabilized using 0.2% Triton X-100 for 10 min at room temperature, and incubated with γH2AX primary antibody (cat. no. 9718; 1:200) at 4°C overnight and Alexa Fluor-488 goat anti-rabbit immunoglobulin G (H+L) secondary antibody (cat. no. A0423; 1:500) (Beyotime Institute of Biotechnology) for 2 h at room temperature. The nuclei were stained with DAPI (Beyotime Institute of Biotechnology). Images were captured using a fluorescence microscope (magnification, x200; Olympus BX-51; Olympus Corp., Tokyo, Japan).

**Cycloheximide (CHX) chase assay.** Kyse450 and EC1 cells were pretreated with 0.6 μM MLN4924 for 18 h to increase the basal protein level of proteins. Cells were then washed with PBS to remove residual drug and divided into 2 groups, which were further treated with 50 μg/ml CHX (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China) or CHX+MLN4924 (0.6 μM) for indicated times and then collected for western blot analysis, as aforementioned.

**Statistical analysis.** For Figs. 1A, 3B and 4A, the statistical significance of differences between groups was assessed using SPSS 17 software (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance followed by a least-significant difference post hoc test was used to compare between multiple groups. For Fig. 4B, the statistical significance of differences between
CDDP and MLN+CDDP was assessed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA. Unpaired Student’s t-test was used for the comparison of parameters between groups. P<0.05, “P<0.01, “”P<0.001 vs. 0 µM unless marked otherwise; n=3. Error bars, standard deviation. (B) MLN induced G2/M cell cycle arrest. EC1 and Kyse450 cells were treated with MLN at different concentration for 24 h, followed by propidium iodide staining and FACS analysis for cell cycle profile. (C) MLN induced accumulation of Wee1, p21, p27, cyclin B and decrease of p-H3. EC1 and Kyse450 cells were treated with MLN at indicated concentration for 72 h, and subjected to western blotting. GAPDH served as a loading control. p21, cyclin-dependent kinase inhibitor 1A; p27, cyclin-dependent kinase inhibitor 1B; Wee1, Weel-like protein kinase; CHX, cyclohexamide; MLN, MLN4924.

CDDP and MLN+CDDP was assessed using GraphPad Prism 5 software (GraphPad Software, Inc., La Jolla, CA, USA. Unpaired Student’s t-test was used for the comparison of parameters between groups. P<0.05 was considered to indicate a statistically significant difference. Data is presented as the mean ± standard.

Results

Targeting neddylation by MLN4924 inhibited the proliferation of ESCC cells. To assess the anticancer function of MLN4924 on esophageal cancer cells, the present study assessed the effect of MLN4924 on cell cycle progression was evaluated using PI staining. MLN4924 induced a marked G2-M cell cycle arrest in the 2 treated cell lines in a dose-dependent manner (Fig. 1B). MLN4924 also induced accumulation of p21, p27, inhibitor of G2-M phase transition Weel (26) and an increase in cyclin B, accompanied by a decrease in the level of phosphohistone H3 (p-H3), a hallmark of M-phase cells (27), indicating that MLN4924-treated cells were arrested at the G2 phase (Fig. 1C). Furthermore, following the blocking of protein synthesis using CHX, the protein stability of p21, p27 and Weel were markedly increased.

Neddylation inhibition with MLN4924 triggered G2 cell cycle arrest of ESCC cells. To investigate the mechanism of cell growth inhibition, the effect of MLN4924 on cell cycle progression was evaluated using PI staining. MLN4924 induced a marked G2-M cell cycle arrest in the 2 treated cell lines in a dose-dependent manner (Fig. 1B). MLN4924 also induced accumulation of p21, p27, inhibitor of G2-M phase transition Weel (26) and an increase in cyclin B, accompanied by a decrease in the level of phosphohistone H3 (p-H3), a hallmark of M-phase cells (27), indicating that MLN4924-treated cells were arrested at the G2 phase (Fig. 1C). Furthermore, following the blocking of protein synthesis using CHX, the protein stability of p21, p27 and Weel were markedly increased.
LIN et al.: MLN4924 INDUCES G2 ARREST, DNA DAMAGE AND CHEMOSENSITIZATION IN ESCC CELLS

MLN4924 induces DNA damage response. Activation of the DNA damage response is an important property of cytotoxic drugs; the expression of γH2AX was therefore determined to detect DNA double-strand breaks by immunofluorescence and western blotting. MLN4924 induced sustained γH2AX foci in the EC1 and Kyse450 cells in a dose-dependent manner (Fig. 3A and B), which was further confirmed by western blotting (Fig. 3C). MLN4924 treatment increased the level of DNA damage response, indicating that G2-phase cell cycle arrest may be attributable to the accumulation of cell cycle-associated proteins.
of CDT1 and ORC1 proteins in a dose-dependent manner (Fig. 3C). These results implied that the accumulation of DNA-replication licensing proteins CDT1 and ORC1, known CRL substrates (28), partially contributed to the induction of DNA damage by MLN4924 treatment.

MLN4924 enhances the cytotoxicity of CDDP to ESCC cells. To assess the function of MLN4924 as a novel chemosensitizer to increase the anti-ESCC activity of CDDP, ESCC EC1 and Kyse450 cell lines were treated with MLN4924, CDDP or the 2 together. Results demonstrated that MLN4924 significantly enhanced the cytotoxicity of CDDP and inhibited cell viability (Fig. 4A; P<0.001) and clonogenic cell survival (Fig. 4B). The combination of MLN4924 with CDDP markedly enhanced apoptosis compared with either single agent, which is evident by the increased percentage of Annexin V-positive (Fig. 5A) or caspase-3 active cells (Fig. 5B) and evaluated expression of cleaved-PARP (Fig. 5C).

Discussion

Previous studies demonstrated that MLN4924 inhibited the growth of a broad panel of cancer cells in vitro and in vivo (3,8,15,29-31). On the basis of its promising anticancer efficacy and tolerated toxicity, MLN4924 has undergone preclinical or phase I clinical trials for multiple human malignancies (17-19). Mechanistically, MLN4924 blocks cullin neddylation, inactivates CRL, induces the accumulation of tumor-suppressive CRL substrates and causes DNA damage, cell cycle arrest, cellular senescence and apoptosis in a tumor cell-specific manner (3,7,15,29,31). To date, the detailed mechanism of MLN4924 on cell proliferation inhibition in human ESCC cells requires further investigation. The present study demonstrated that MLN4924 could induce G2 cell cycle arrest in ESCC cells. At the same time, MLN4924 significantly enhanced the protein stability of p21, p27 and Wee1, which is in accordance with previous studies (9,15), where they indicate that all of the 3 proteins
serve an important function in MLN4924-induced G2 cell cycle arrest (23).

G2/M-phase arrest is a crucial response to DNA damage in the majority of cancer cells (32). The present study found that MLN4924 treatment triggered DNA damage response in ESCC cells, as demonstrated by the appearance of γH2AX. Further analysis revealed that 2 well-known CRL substrates, CDT1 and ORC1, were accumulated in MLN4924-treated ESCC cells; their overexpression was known to trigger DNA damage response (3,11,29).

CDDP is a first-line chemotherapeutic agent for the treatment of ESCC (2). However, the toxicity and the development of resistance often limit its efficacy (33). Previously, a series of studies revealed that MLN4924 could be used as a sensitizer to chemotherapy: MLN4924 has been demonstrated to overcome resistance to a range of chemotherapeutics, including CDDP (20,21), carboplatin (21,34), bleomycin (35), doxorubicin (35) and etoposide (35) resistance in ovarian tumor cell lines in vitro and in vivo. MLN4924 significantly augmented the cytotoxicity of CDDP against CDDP-resistant cells in cervical carcinoma xenografts (22). The results of the present study revealed that the addition of MLN4924 significantly improved the efficacy of CDDP by enhancing the incidence of apoptosis in ESCC cells. These results indicate that MLN4924 could be used alone or in combination for the treatment of human ESCC in future studies.

The present study demonstrated that inactivating the neddylation pathway by MLN4924 suppressed the growth of esophageal cancer cells by triggering G2 cell cycle arrest and inducing DNA damage. Furthermore, the combination of MLN4924 and CDDP more effectively inhibited cell growth compared with treatment with either single drug by enhancing apoptosis in esophageal cancer cells. These results extend the understanding of the function of MLN4924 and propose its use in the treatment of esophageal cancer in single treatment or in combination.

Acknowledgements

The authors thank Professor Guoqiang Zhao from Zhengzhou University (Zhengzhou, China) for kindly providing the EC1 and Kyse450 cell lines. The present study was supported by
the National Natural Science Foundation of China (grant nos. 81011012, 81101894 and 81672421), the Outstanding Young Talent Research Fund of Zhengzhou University (grant no. 51999223), the Research Foundation of Education Bureau of Henan, China (grant no. 15A310024) and the Student's Platform for Innovation and Entrepreneurship Training Program of Zhengzhou University (grant no. 2016xjxm341).

References